New drug combo shows promise for Hard-to-Treat breast cancer
Disease control
Terminated
This study tests two treatments for people with a certain type of advanced breast cancer (HRD-positive, HER2-negative). It will compare the drug fluzoparib alone versus fluzoparib combined with camrelizumab. The goal is to see if the combination works better at shrinking tumors o…
Phase: PHASE2 • Sponsor: wang shusen • Aim: Disease control
Last updated May 15, 2026 11:54 UTC